Marc Couke's resignation leads to expanded role for Sharon Kochan at new-look Perrigo

28 April 2016

Ireland-based Perrigo (NYSE: PRGO) has announced that Sharon Kochan will lead the expansion of the company’s branded consumer healthcare (BCH) segment.

It follows the resignation of Marc Couke as vice president and general manager of BCH and comes days after the news that Perrigo’s chief executive Joseph Papa had been recruited to turn around the fortunes of struggling Canadian firm Valeant Pharmaceuticals (TSX: VRX).

Mr Kochan, who in 2012 became Perrigo's executive vice president and general manager, international, will now have increased responsibilities including providing leadership and strategic direction in BCH.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK